000			03642nam a22003975i 4500
001			85448
003			ES-MaUEC
005			20230207040511.0
007			cr nn 008mamaa
008			160324s2016 gw | s |||| 0|eng d
020			_a9783319283685
040			_aES-MaUEC
050		4	_aQR84.5 _bN499 2016
082	0	4	_a579
245	0	0	_aNew Weapons to Control Bacterial Growth _cedited by Tomas G Villa, Miguel Vinas
250			_a1st ed.
260			_aCham _bSpringer International Publishing _c2016
300			_a1 recurso en línea (VI, 556 p.) _b78 ilustraciones, 60 ilustraciones en color
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_aBacteriocins -- Control of bacterial growth through RNA degradation -- Control of Pathogenic Clostridia -- DNA-synthesizing enzymes as antibacterial targets -- Inhibition of bacterial efflux pump activity as a way to control microbial growth -- Bacterial protease as targets to control bacterial growth -- Quorum sensing and competence stimulation as targets for antimicrobial chemotherapy -- Transcriptomics as a tool to finding new antibacterial targets -- The case of Lipid II: the Achilleś heel of bacteria -- Microbiome Control in the Prevention and Early Management of Cancer -- Targets against Helicobacter pylori and other tumor-producing bacteria -- Intestinal Microbiota: First barrier against gut-affecting pathogens -- Fecal matter implantation as a way to fight diarrhea-causing microorganisms -- Different approaches for searching new microbial antibiotics controlling bacterial growth -- Synthetic peptides as antimicrobials -- The use of nanoparticles for antimicrobials delivery -- Predation and competition: bacteriophages and bacteria as antimicrobial agents
520			_aWritten by specialists in the different fields, this book presents new perspectives and insights into strategies and weapons to fight microbial infections. It also reviews the zstate of the arty of alternative treatment approaches and new therapeutic agents to deal with infections caused by multidrug-resistant microorganisms. In an era of accumulated resistance to current antibiotics, it is vital that this is undertaken without further delay. Aspects discussed include the control of RNA synthesis, the use of bacteriocins or enzybiotics (bacteriophages or purified lysins), the specific control of pathogenic clostridia, the design of new drugs affecting DNA synthesis in bacteria, the use of fecal-matter transplant strategies, the specific control of quorum sensing responses in bacteria, the use of new peptides as antibiotics and new ways to control bacteria that cause cancer, such as Helicobacter pylori cancers
710	2		_aSpringerLink (Online service) _0Local _9106996
942			_2lcc _cLE
988			_aEBOOK, EBSPRINGER
650		7	_aBacterias _0comprobar BNE19900965808 _2embne _9138901
650		7	_9405049 _aMicrobiología médica _0comprobar BNE19900963008 _2embne
700	1		_aGonzález Villa, Tomás _0n 93027814 _eeditor literario _948419
700	1		_aVinas, Miguel. _eeditor literario _998412 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-28368-5 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_ai9783319283685
907			_a.b1294726x _b16-10-17 _c21-11-16
998			_am _a_alco _a_vill _b17-08-17 _cm _dz _ek _feng _ggw _h0
945			_aQR84.5 N499 2016 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11590865 _z06-04-17
999			_c85448 _d85448 _x1